UY38684A - Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb) - Google Patents

Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)

Info

Publication number
UY38684A
UY38684A UY0001038684A UY38684A UY38684A UY 38684 A UY38684 A UY 38684A UY 0001038684 A UY0001038684 A UY 0001038684A UY 38684 A UY38684 A UY 38684A UY 38684 A UY38684 A UY 38684A
Authority
UY
Uruguay
Prior art keywords
hbv
virus
new
piperazines
oxalyl
Prior art date
Application number
UY0001038684A
Other languages
English (en)
Inventor
Andreas Urban Dr
Susanne Bonsmann
Alastair Donald Dr
Elena Detta
Thomas Goldner Dr
Àngel Pericàs Brondo Miquel
Alza Barrios Esther
Justine Raymond
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of UY38684A publication Critical patent/UY38684A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere generalmente a nuevos agentes antivirales. Específicamente, la presente invención se refiere a compuestos que pueden inhibir la(s) proteína(s) codificadas por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, composiciones que comprenden tales compuestos, métodos para inhibir la replicación viral del VHB, métodos para tratar o prevenir la infección por VHB, y procesos e intermedios para fabricar los compuestos.
UY0001038684A 2019-04-30 2020-05-04 Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb) UY38684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19172008 2019-04-30
EP19172402 2019-05-02

Publications (1)

Publication Number Publication Date
UY38684A true UY38684A (es) 2020-11-30

Family

ID=70456795

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038684A UY38684A (es) 2019-04-30 2020-05-04 Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)

Country Status (17)

Country Link
US (1) US20220227737A1 (es)
EP (1) EP3962909B1 (es)
JP (1) JP2022533008A (es)
KR (1) KR20220003023A (es)
CN (1) CN113748111A (es)
AU (1) AU2020266258A1 (es)
BR (1) BR112021021652A2 (es)
CA (1) CA3138380A1 (es)
CL (1) CL2021002798A1 (es)
CU (1) CU20210090A7 (es)
EC (1) ECSP21080338A (es)
IL (1) IL287269A (es)
MX (1) MX2021013105A (es)
SG (1) SG11202111493WA (es)
TW (1) TWI753418B (es)
UY (1) UY38684A (es)
WO (1) WO2020221811A1 (es)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
WO2001006840A1 (en) 1999-04-23 2001-02-01 Jonathan Dallas Toye Sheet fastening and anchoring component
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
RU2441004C1 (ru) * 2007-12-19 2012-01-27 Дженентек, Инк. 5-анилиноимидазопиридины и способы их применения
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
CN104302626B (zh) 2012-01-06 2016-09-07 爱尔兰詹森科学公司 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途
KR102122244B1 (ko) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
JP6285440B2 (ja) 2012-08-28 2018-02-28 ヤンセン・サイエンシズ・アイルランド・ユーシー 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CN108047115B (zh) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2015073774A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3114128B1 (en) 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
MY196243A (en) 2014-03-28 2023-03-24 Sunshine Lake Pharma Co Ltd Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
CA2948580A1 (en) 2014-05-09 2015-11-12 Adam Zlotnick Methods and compositions for treating hepatitis b virus infections
WO2016023877A1 (en) 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
CA2969557A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
CN107531691A (zh) * 2014-12-30 2018-01-02 诺维拉治疗公司 治疗乙型肝炎感染的衍生物和方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
KR102359212B1 (ko) 2015-03-16 2022-02-08 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA2982811A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017013046A1 (en) 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
EP3372606B1 (en) 2015-11-04 2020-04-08 Qilu Pharmaceutical Co., Ltd Crystal form, preparation method and intermediate of dihydropyrido ring compound
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
PL3426245T3 (pl) 2016-03-07 2023-05-22 Enanta Pharmaceuticals, Inc. Środki przeciwwirusowe zapalenia wątroby typu b
US10519145B2 (en) 2016-04-06 2019-12-31 Shanghai Zhimeng Biopharma Co., Ltd. Pyrazole-oxazolidinone compound for anti-hepatitis B virus
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011162A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3484886B1 (en) 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3036245C (en) 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
SG11201908569QA (en) 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN110582500B (zh) 2017-05-04 2022-04-05 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
CN109952305B (zh) 2017-07-27 2022-06-21 江苏恒瑞医药股份有限公司 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
TW201912153A (zh) 2017-08-30 2019-04-01 加拿大商愛彼特生物製藥公司 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly

Also Published As

Publication number Publication date
CN113748111A (zh) 2021-12-03
ECSP21080338A (es) 2021-12-30
TW202106678A (zh) 2021-02-16
CA3138380A1 (en) 2020-11-05
MX2021013105A (es) 2021-11-17
KR20220003023A (ko) 2022-01-07
US20220227737A1 (en) 2022-07-21
EP3962909A1 (en) 2022-03-09
CU20210090A7 (es) 2022-06-06
CL2021002798A1 (es) 2022-06-10
TWI753418B (zh) 2022-01-21
AU2020266258A1 (en) 2021-12-23
IL287269A (en) 2021-12-01
AU2020266258A2 (en) 2022-05-05
SG11202111493WA (en) 2021-11-29
BR112021021652A2 (pt) 2021-12-21
JP2022533008A (ja) 2022-07-21
EP3962909B1 (en) 2023-10-04
WO2020221811A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
MX2020004838A (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
UY37699A (es) Compuestos fusionados de indazol piridona como antivirales
CL2021001116A1 (es) Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
CL2021001117A1 (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CR20150454A (es) Compuestos amida para el tratamiento de vih
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
ECSP21078893A (es) Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38684A (es) Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)
UY38681A (es) Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38439A (es) Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
EA202192969A1 (ru) Новые оксалилпиперазины, активные против вируса гепатита b (вгв)
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202192965A1 (ru) Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв)